Abstract
Despite prolific efforts to characterize the antibody response to human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) mono-infections, the response to chronic co-infection with these two ever-evolving viruses is poorly understood. Here, we investigate the antibody repertoire of a chronically HIV-1/HCV co-infected individual using linking B cell receptor to antigen specificity through sequencing (LIBRA-seq). We identify five HIV-1/HCV cross-reactive antibodies demonstrating binding and functional cross-reactivity between HIV-1 and HCV envelope glycoproteins. All five antibodies show exceptional HCV neutralization breadth and effector functions against both HIV-1 and HCV. One antibody, mAb688, also cross-reacts with influenza and coronaviruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We examine the development of these antibodies using next-generation sequencing analysis and lineage tracing and find that somatic hypermutation established and enhanced this reactivity. These antibodies provide a potential future direction for therapeutic and vaccine development against current and emerging infectious diseases. More broadly, chronic co-infection represents a complex immunological challenge that can provide insights into the fundamental rules that underly antibody-antigen specificity.
Original language | English (US) |
---|---|
Article number | 112044 |
Journal | Cell Reports |
Volume | 42 |
Issue number | 2 |
DOIs | |
State | Published - Feb 28 2023 |
Keywords
- CP: Immunology
- HIV1/HCV co-infection
- LIBRA-seq
- antibody
- antigen cross-reactivity
- antiviral antibodies
- broadly neutralizing
- somatic hypermutation
- vaccine
ASJC Scopus subject areas
- General Biochemistry, Genetics and Molecular Biology